Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 6
2004 8
2005 6
2006 12
2007 20
2008 12
2009 14
2010 14
2011 30
2012 25
2013 38
2014 23
2015 22
2016 39
2017 29
2018 47
2019 46
2020 43
2021 36
2022 24
2023 32
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

441 results

Results by year

Filters applied: . Clear all
Page 1
Dynamic disability measures decrease the clinico-radiological gap in people with severely affected multiple sclerosis.
Jakimovski D, Weinstock-Guttman B, Burnham A, Weinstock Z, Wicks TR, Ramanathan M, Sciortino T, Ostrem M, Suchan C, Dwyer MG, Reilly J, Bergsland N, Schweser F, Kennedy C, Young-Hong D, Eckert SP, Hojnacki D, Benedict RH, Zivadinov R. Jakimovski D, et al. Among authors: zivadinov r. Mult Scler Relat Disord. 2024 Apr 22;87:105630. doi: 10.1016/j.msard.2024.105630. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 38678969
How to and should we target EBV in MS?
Eckert S, Jakimovski D, Zivadinov R, Hicar M, Weinstock-Guttman B. Eckert S, et al. Among authors: zivadinov r. Expert Rev Clin Immunol. 2024 Mar 15:1-12. doi: 10.1080/1744666X.2024.2328739. Online ahead of print. Expert Rev Clin Immunol. 2024. PMID: 38477887
Final report of the PROTEMBO C Trial: a prospective evaluation of a novel cerebral protection device during TAVI.
Fezzi S, Jagielak D, Targonski R, Schmidt T, Frerker C, Witkowski AR, Lauterbach M, Leick J, Erglis A, Narbute I, Grygier M, Misterski M, Frank D, Abdel-Wahab M, Wilde J, Adam M, Gatto F, Zivadinov R, Dwyer M, Werner N, Mylotte D. Fezzi S, et al. Among authors: zivadinov r. EuroIntervention. 2024 Feb 19;20(4):e264-e267. doi: 10.4244/EIJ-D-23-00743. EuroIntervention. 2024. PMID: 38389472 Free article. No abstract available.
Proteomic signatures of physical, cognitive, and imaging outcomes in multiple sclerosis.
Jalaleddini K, Jakimovski D, Keshavan A, McCurdy S, Leyden K, Qureshi F, Ghoreyshi A, Bergsland N, Dwyer MG, Ramanathan M, Weinstock-Guttman B, Benedict RH, Zivadinov R. Jalaleddini K, et al. Among authors: zivadinov r. Ann Clin Transl Neurol. 2024 Mar;11(3):729-743. doi: 10.1002/acn3.51996. Epub 2024 Jan 17. Ann Clin Transl Neurol. 2024. PMID: 38234075 Free PMC article.
Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
Jakimovski D, Kavak KS, Coyle PK, Goodman AD, Gottesman M, Zivadinov R, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium (NYSMSC). Jakimovski D, et al. Among authors: zivadinov r. J Neurol. 2024 Feb;271(2):711-722. doi: 10.1007/s00415-023-12099-x. Epub 2023 Nov 23. J Neurol. 2024. PMID: 37995009
441 results